SCHEMBL4018316

SCHEMBL4018316

C[C@H](Cc1cccc(CC(=O)NCc2ccc(CNC(=O)c3cccc4ccccc34)cc2)c1)NC[C@@H](O)c1ccc(O)c(CO)c1

nearest known ligand 0.80

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 20/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4018309 1.00 ADRB2 (0.80) ADRB2
SCHEMBL4255298 0.90 ADRB2 (0.84) ADRB2
SCHEMBL4259717 0.90 ADRB2 (0.84) ADRB2
SCHEMBL4260727 0.89 ADRB2 (1.00) ADRB2
SCHEMBL4260722 0.89 ADRB2 (1.00) ADRB2
SCHEMBL5654211 0.89 ADRB2 (1.00) ADRB2
SCHEMBL4260851 0.86 ADRB2 (0.86) ADRB2
SCHEMBL4260847 0.86 ADRB2 (0.86) ADRB2
SCHEMBL4255077 0.86 ADRB2 (0.90) ADRB2
SCHEMBL4406620 0.86 ADRB2 (0.90) ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482487-B2 Phenylaminoethanol derivatives as β2 receptor agonists PFIZER INC (US) 2009-01-27 US claimed
EP-1577292-A1 Phenylaminoethanol derivatives as beta2 receptor agonists Pfizer Limited (GB) 2005-09-21 EP claimed
US-7482487-B2 Phenylaminoethanol derivatives as β2 receptor agonists PFIZER INC (US) 2009-01-27 US disclosed
US-20070264262-A1 Phenylaminoethanol Derivates as Beta 2 Receptor Agonists BROWN ALAN D 2007-11-15 US disclosed
EP-1577292-A1 Phenylaminoethanol derivatives as beta2 receptor agonists Pfizer Limited (GB) 2005-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070264262-A1 Phenylaminoethanol Derivates as Beta 2 Receptor Agonists ADRB2, ADRB1, ADRA2C ADRB2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.